Page last updated: 2024-11-05

thalidomide and Abnormalities, Maxillofacial

thalidomide has been researched along with Abnormalities, Maxillofacial in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhao, Y1
Chen, Q1
Chen, L1
Shen, SGF1
Dai, J1

Other Studies

1 other study available for thalidomide and Abnormalities, Maxillofacial

ArticleYear
Thalidomide leads to mandible hypoplasia through inhibiting angiogenesis and secondary hemorrhage in the fetal craniofacial region in rabbits.
    Toxicology letters, 2020, Feb-01, Volume: 319

    Topics: Animals; Craniofacial Abnormalities; Down-Regulation; Female; Hemorrhage; Mandible; Maxillofacial Ab

2020